Trial Profile
Natalizumab (Tysabri) for the treatment of anti-Hu associated paraneoplastic neurological syndromes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2020
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Neurological disorders
- Focus Therapeutic Use
- 22 Dec 2020 Status changed from not yet recruiting to completed.
- 01 Jun 2016 Eudra reports recruiting with start date (03-02-2016), but NTR reports status as not yet recruiting with start date (15-02-2016), retained NTR since it is location specific.
- 08 Mar 2016 New trial record